ToxSci Advance Access originally published online on September 14, 2005
Toxicological Sciences 2005 88(2):562-575; doi:10.1093/toxsci/kfi316
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores













,1

* Howard Hughes Medical Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231;
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231;
Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231;
Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231; ¶ Department of Comparative Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231; || Department of Oncology, University of Michigan, Ann Arbor, Michigan, 48104; ||| Cardiovascular Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892
Received June 28, 2005; accepted September 6, 2005
Clostridium novyi-NT (C. novyi-NT) spores have been shown to be potent therapeutic agents in experimental tumors of mice and rabbits. In the present study, pharmacologic and toxicologic studies were performed to better understand the factors influencing the efficacy and toxicity of this form of therapy. We found that spores were rapidly cleared from the circulation by the reticuloendothelial system. Even after large doses were administered, no clinical toxicity was observed in healthy mice or rabbits. The spores were also not toxic in mice harboring poorly vascularized non-neoplastic lesions, including myocardial infarcts. In tumor-bearing mice, toxicity appeared related to tumor size and spore dose, as expected with any bacterial infection. However, there was no laboratory or histopathologic evidence of sepsis, and the toxicity could be effectively controlled by simple hydration.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S.-C. Liu, G-O. Ahn, M. Kioi, M.-J. Dorie, A. V. Patterson, and J. M. Brown Optimized Clostridium-Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104 Cancer Res., October 1, 2008; 68(19): 7995 - 8003. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cheong, X. Huang, K. Thornton, L. A. Diaz Jr., and S. Zhou Targeting Cancer with Bugs and Liposomes: Ready, Aim, Fire Cancer Res., October 15, 2007; 67(20): 9605 - 9608. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Plomp, J. M. McCaffery, I. Cheong, X. Huang, C. Bettegowda, K. W. Kinzler, S. Zhou, B. Vogelstein, and A. J. Malkin Spore Coat Architecture of Clostridium novyi NT Spores J. Bacteriol., September 1, 2007; 189(17): 6457 - 6468. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhao, M. Yang, H. Ma, X. Li, X. Tan, S. Li, Z. Yang, and R. M. Hoffman Targeted therapy with a salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res., August 1, 2006; 66(15): 7647 - 7652. [Abstract] [Full Text] [PDF] |
||||

